PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history.
about
The dynamic relationship between innate immune biomarkers and interferon-based treatment effects and outcome in hepatitis C virus infection is altered by telaprevirDetection of anti-cytokine antibodies and their clinical relevance.Immune Evasion Strategies during Chronic Hepatitis B and C Virus InfectionComplementary Effects of Interleukin-15 and Alpha Interferon Induce Immunity in Hepatitis B Virus Transgenic Mice.The serum IL-23 level predicts the response to pegylated interferon therapy in patients with chronic hepatitis B.Circulating miR-210 and miR-22 combined with ALT predict the virological response to interferon-alpha therapy of CHB patients.
P2860
PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history.
@en
type
label
PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history.
@en
prefLabel
PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history.
@en
P2093
P2860
P356
P1476
PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history
@en
P2093
Elisabetta Degasperi
Massimo Colombo
Mauro Viganò
P2860
P304
P356
10.1586/ERI.13.37
P577
2013-05-01T00:00:00Z